We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

6078:HKEXHygeia Healthcare Holdings Co., Ltd. Analysis

Data as of 2026-06-03 - not real-time

¥1,358.00

Latest Price

7/10Risk

Risk Level: Medium

Executive Summary

Value HR Co.,Ltd. is trading at ¥1,358, which sits below its 20‑day (¥1,378), 50‑day (¥1,421) and 200‑day (¥1,537) simple moving averages, signalling a bearish price momentum. The RSI of 42.5 suggests the stock is not yet oversold, while the MACD line has just edged above its signal line, offering a faint bullish hint that may not be enough to reverse the trend. Volatility is elevated at 28% over the past 30 days, yet the beta is virtually zero (0.01), indicating the price swings are largely company‑specific rather than market‑driven. Fundamental metrics paint a picture of overvaluation: the trailing P/E of 57.8 is more than double the industry average of 27, and the P/B of 5.48 further confirms a premium valuation. Although the dividend yield is 1.99%, the payout ratio exceeds 110% and operating cash flow is zero, raising doubts about dividend sustainability. Leverage is high, with a debt‑to‑equity of 86% and net debt of roughly ¥1.9 bn, while profitability is modest (ROE 9%, operating margin 7.7%). The stock has endured a max drawdown of 28% and faces a near‑term support at ¥1,332 and resistance at ¥1,428. Despite an “Extreme Greed” market sentiment, the combination of technical weakness, lofty multiples, and financial strain suggests caution.

Market Outlook

Short Term

< 1 year
Cautious
Model confidence: 6/10

Key Factors

  • Price below key moving averages indicating bearish momentum
  • Extreme overvaluation relative to industry peers
  • Unsustainable dividend payout and zero operating cash flow

Medium Term

1–3 years
Neutral
Model confidence: 5/10

Key Factors

  • Increasing trading volume may support a bounce toward resistance
  • High leverage and weak cash generation limit upside potential
  • Valuation remains stretched despite modest revenue growth

Long Term

> 3 years
Neutral
Model confidence: 5/10

Key Factors

  • Aging Japanese population provides secular demand for health‑management services
  • Potential upside if the company can deleverage and improve cash flow
  • Current valuation premium and financial weaknesses warrant a wait‑and‑see approach

Key Metrics & Analysis

Financial Health

Revenue Growth12.60%
Profit Margin5.79%
P/E Ratio57.8
ROE9.07%
ROA2.98%
Debt/Equity86.33
P/B Ratio5.5
Industry P/E27.2

Technical Analysis

TrendBearish
RSI42.6
Support¥1,332.00
Resistance¥1,428.00
MA 20¥1,378.00
MA 50¥1,420.80
MA 200¥1,537.01
MACDBullish
VolumeIncreasing
Fear & Greed Index92.75

Valuation

GradeOvervalued
TypeValue
Dividend Yield1.99%

Risk Assessment

Beta0.01
Volatility28.04%
Sector RiskMedium
Reg. RiskMedium
Geo RiskLow
Currency RiskLow
Liquidity RiskMedium

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.